289 related articles for article (PubMed ID: 10930481)
1. Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Nukui Y; Picozzi VJ; Traverso LW
Am J Surg; 2000 May; 179(5):367-71. PubMed ID: 10930481
[TBL] [Abstract][Full Text] [Related]
2. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
Picozzi VJ; Kozarek RA; Traverso LW
Am J Surg; 2003 May; 185(5):476-80. PubMed ID: 12727570
[TBL] [Abstract][Full Text] [Related]
3. Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
Katz MH; Wolff R; Crane CH; Varadhachary G; Javle M; Lin E; Evans DB; Lee JE; Fleming JB; Pisters PW
Ann Surg Oncol; 2011 Dec; 18(13):3615-22. PubMed ID: 21701927
[TBL] [Abstract][Full Text] [Related]
4. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience.
Yeo CJ; Abrams RA; Grochow LB; Sohn TA; Ord SE; Hruban RH; Zahurak ML; Dooley WC; Coleman J; Sauter PK; Pitt HA; Lillemoe KD; Cameron JL
Ann Surg; 1997 May; 225(5):621-33; discussion 633-6. PubMed ID: 9193189
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study.
Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR
Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621
[TBL] [Abstract][Full Text] [Related]
6. Interferon-based Adjuvant Chemoradiation for Resected Pancreatic Head Cancer: Long-term Follow-up of the Virginia Mason Protocol.
Rocha FG; Hashimoto Y; Traverso LW; Dorer R; Kozarek R; Helton WS; Picozzi VJ
Ann Surg; 2016 Feb; 263(2):376-84. PubMed ID: 25775069
[TBL] [Abstract][Full Text] [Related]
7. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
Chakravarthy A; Abrams RA; Yeo CJ; Korman LT; Donehower RC; Hruban RH; Zahurek ML; Grochow LB; O'Reilly S; Hurwitz H; Jaffee EM; Lillemoe KD; Cameron JL
Int J Radiat Oncol Biol Phys; 2000 Nov; 48(4):1089-96. PubMed ID: 11072167
[TBL] [Abstract][Full Text] [Related]
8. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up.
Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG
HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923
[TBL] [Abstract][Full Text] [Related]
9. Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
Thomas CR; Weiden PL; Traverso LW; Thompson T
Am J Clin Oncol; 1997 Apr; 20(2):161-5. PubMed ID: 9124192
[TBL] [Abstract][Full Text] [Related]
10. Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
Knaebel HP; Märten A; Schmidt J; Hoffmann K; Seiler C; Lindel K; Schmitz-Winnenthal H; Fritz S; Herrmann T; Goldschmidt H; Krempien R; Mansmann U; Debus J; Diehl V; Büchler MW
BMC Cancer; 2005 Apr; 5():37. PubMed ID: 15826316
[TBL] [Abstract][Full Text] [Related]
11. The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
Regine WF; John WJ; McGrath P; Strodel WE; Mohiuddin M
J Hepatobiliary Pancreat Surg; 2000; 7(1):53-7. PubMed ID: 10982592
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E
Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835
[TBL] [Abstract][Full Text] [Related]
13. Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
Carducci MA; Abrams RA; Yeo CJ; Hruban RH; Zahurak ML; Cameron JL; Grochow LB
Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):143-50. PubMed ID: 8641911
[TBL] [Abstract][Full Text] [Related]
14. Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
Schmidt J; Abel U; Debus J; Harig S; Hoffmann K; Herrmann T; Bartsch D; Klein J; Mansmann U; Jäger D; Capussotti L; Kunz R; Büchler MW
J Clin Oncol; 2012 Nov; 30(33):4077-83. PubMed ID: 23008325
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N
Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
You DD; Lee HG; Heo JS; Choi SH; Choi DW
J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512
[TBL] [Abstract][Full Text] [Related]
17. Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031.
Picozzi VJ; Abrams RA; Decker PA; Traverso W; O'Reilly EM; Greeno E; Martin RC; Wilfong LS; Rothenberg ML; Posner MC; Pisters PW;
Ann Oncol; 2011 Feb; 22(2):348-54. PubMed ID: 20670978
[TBL] [Abstract][Full Text] [Related]
18. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Spitz FR; Abbruzzese JL; Lee JE; Pisters PW; Lowy AM; Fenoglio CJ; Cleary KR; Janjan NA; Goswitz MS; Rich TA; Evans DB
J Clin Oncol; 1997 Mar; 15(3):928-37. PubMed ID: 9060530
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest.
Vokes EE; Haraf DJ; Drinkard LC; Hoffman PC; Ferguson MK; Vogelzang NJ; Watson S; Lane NJ; Golomb HM
Cancer Chemother Pharmacol; 1995; 35(4):304-12. PubMed ID: 7530173
[TBL] [Abstract][Full Text] [Related]
20. Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
Pisters PW; Abbruzzese JL; Janjan NA; Cleary KR; Charnsangavej C; Goswitz MS; Rich TA; Raijman I; Wolff RA; Lenzi R; Lee JE; Evans DB
J Clin Oncol; 1998 Dec; 16(12):3843-50. PubMed ID: 9850029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
